Advanced search
Publication Cover
Cancer Management and Research Volume 14, 2022 - Issue
Submit an article Journal homepage
231
Views
4
CrossRef citations to date
0
Altmetric
Original Research

The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study

Feng ZhangPrecision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, People’s Republic of China
,
Yuyang WangPrecision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, People’s Republic of China
,
Fangfang YangPrecision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, People’s Republic of China
,
Yuming ZhangPrecision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, People’s Republic of China
,
Man JiangPrecision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, People’s Republic of ChinaCorrespondence[email protected] [email protected]
&
Xiaochun ZhangPrecision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-3271-7260
ORCID Icon
Pages 535-546 | Published online: 09 Feb 2022

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Zhitao Chen, Yahui He, Chenchen Ding, Jun Chen, Yangjun Gu, Min Xiao & Qiyong Li. (2023) Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study. OncoTargets and Therapy 16, pages 923-935.
Read now

Articles from other publishers (3)

Meng Wang, Qida Hu, Junming Huang, Fu Zhang, Zhuo Yao, Shiyi Shao, Xinyu Zhao & Tingbo Liang. (2023) In Situ Formed ROS‐Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic Ductal Adenocarcinoma. Advanced Healthcare Materials 12:20.
Crossref
Yunkai Yang, Huan Zhang, Shanshan Huang & Qian Chu. (2023) KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration. Journal of Clinical Medicine 12:2, pages 709.
Crossref
Changchang Lu, Yahui Zhu, Hao Cheng, Weiwei Kong, Linxi Zhu, Lei Wang, Min Tang, Jun Chen, Qi Li, Jian He, Aimei Li, Xin Qiu, Dongsheng Chen, Fanyan Meng, Xiaoping Qian, Baorui Liu, Yudong Qiu & Juan Du. (2022) Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer. Frontiers in Oncology 12.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.